TEAL'S PATIENT CARE APPROACH

Who We Are

Teal Health is a women's health company that developed the FDA-authorized Teal Wand™, a vaginal self-collection device for at-home cervical cancer screening. The Teal Wand allows eligible patients to conveniently screen from the comfort of home, with a care model and team of licensed medical providers dedicated to supporting patients from prescription to on-guideline referrals. We are on a mission to help get all women and people with a cervix access to a full cervical cancer screening.

The Teal Wand detects cervical precancer 96% of the time, which is the same as clinician collected samples.

Prescription required ✓
FDA-authorized device and assay ✓
Teal clinician oversight, referrals, and follow-up ✓
Care coordination with referred provider ✓
Managed under ASCCP guidelines ✓

Teal Health is a member of the National Roundtable on Cervical Cancer.

Key Findings from our Clinical Trial

Teal's pivotal FDA study (SELF-CERV) enrolled 609 participants aged 25–65 across 16 U.S. sites. Participants provided a self-collected vaginal sample using the Teal Wand and a clinician-collected cervical sample, both tested with Roche cobas® HPV.[1]

- **96%** sensitivity for CIN2+ (same as clinician sample; relative sensitivity = 1.00).
- **95%** positive agreement for high-risk HPV detection (exceeding endpoint of 87%).
- **98%** self-collected a valid sample using the Teal Wand.
- Strong usability, safety, and shipping stability performance.

The Teal Wand is the **first FDA-authorized** and clinically validated device for at-home self-collection.

All samples are tested at a CLIA-certified laboratory on the FDA-approved Roche cobas primary HPV test, which is validated for use with samples collected with the Teal Wand.[18]

Internal check on test limits false-negative errors, ensuring results are provided only when sufficient sample is collected.

A Proven Method: Boosting Screening and Follow-up with At-Home Self-Collection

Primary HPV testing is the preferred cervical cancer screening test of the American Cancer Society (ACS) and USPSTF (draft guidelines). It is more sensitive than the Pap test (92–98% vs. 50–75%), with strong evidence from eight studies (N=637,241) showing that primary HPV screening detected significantly more CIN3+ than cytology-based screening (RR 1.80; 95% CI, 1.38–2.36).[2-6]

It also **leads to fewer unnecessary procedures than a cotest (Pap+HPV)**. Primary HPV testing every 5 years (followed by appropriate triage) resulted in 60% fewer cervical tests and 12% fewer colposcopies in a woman's lifetime compared to co-testing.[7]

Primary HPV testing also enables vaginal self-collection, which is critical for expanding cervical cancer screening uptake. Cervical cancer screening rates have dropped more than 10% in the last decade, with younger women aged 30-44 years seeing an 11% increase in cervical cancer diagnoses.[8]

More than 1 in 4 women aged 21-65 are behind on their cervical cancer screening.[9]

Fewer than 50% of those diagnosed with cervical cancer were screened in the past 5 years.[10-12]

Evidence from around the world clearly demonstrates that at-home self-collection, using primary HPV tests, increases screening participation toward the goal of disease elimination.

More than 17 countries, ranging in resource levels and healthcare infrastructure, successfully implement at-home self-collection using primary HPV tests.[13-14]

Data from multiple randomized trials and health systems in the U.S. show that mailed at-home HPV test kits significantly boosts screening compared to standard clinic invitations.[15-16]

USPSTF 2024 draft guidelines underscores increased uptake by 32% to 63% with at-home self-collection, especially among underscreened.[17-19] ACS and HRSA updated their screening guidelines to include self-collection for Primary HPV testing and HRSA has mandated insurance coverage by January 2027.[23,24]

We know many women would choose an at-home self-collect approach for a variety of reasons: limited access to in-person care, financial constraints, pain or anxiety with speculum exams, history of sexual trauma, or personal preference. Teal Health's SELF-CERV trial found that **94% of women preferred a clinically validated at-home self-collection option.**

Teal Health is a member of the National Roundtable on Cervical Cancer.

Teal Medical Practice Care Model

Our high-touch approach prioritizes getting patients screened and making sure they complete necessary in-clinic follow-up care. Teal's licensed medical providers – OBGYNs and nurse practitioners – see patients through the entire screening, from prescription to follow-up referrals.

By enabling screening in the patient's setting of choice, your patients can choose to screen at home before they arrive in the clinic with results in hand. You can then spend more valuable in-clinic time on your patients' other comprehensive health needs.

Our clinical workflow replicates the accuracy of in-clinic screening, while expanding access. Each patient's journey is tracked end-to-end, ensuring high-touch personalized support and accountability for every patient to complete their screening and follow-up pathway.

Teal follows screening guidelines* and recommends at-home self-collection for anyone:

- Between the screening ages of 25-65 years
- With a cervix (has not had a full hysterectomy)

Even if you are vaccinated, you should still get screened.

Currently not recommended for anyone who:

- Is pregnant
- Has a history of cancer in the reproductive system, HIV, DES exposure, or immunosuppression
- Had a treatment for cervical precancer (LEEP or cold knife cone)

*American Cancer Society screening guidelines

Eligible patients are educated on how to use the Teal Wand, an **FDA-authorized prescription-only** vaginal self-collection device.

1 Establish Care



2 At-home self-collection

Teal provides resources and reminders to do their at-home collection.

Over 98% of participants in the clinical study collected a valid sample using the Teal Wand.

Patient ships sample via USPS to **CLIA-certified lab**. Sample is run on **FDA-approved cobas HPV test**.

3 CLIA Lab



4 Results & telehealth visit

Teal providers manage results per ASCCP guidelines and shares back to the patient and the in-person care team.

HPV not detected: patient informed of next screening date.

HPV detected: patient attends a virtual follow-up visit with a Teal MD/NP to review results, get support, and discuss referral.

Teal assists patients who need referrals for in-clinic care, leveraging reminders and digital outreach.

5 In-person referral

Teal medical providers meet with every patient to review their screening history and evaluate any symptoms (e.g., abnormal bleeding) and medical history.

Only those patients who are eligible for self-collection, based on established guidelines, are prescribed the Teal Wand.

Providers review all results and refer patients with HPV-positive results for in-clinic follow-ups, per ASCCP guidelines (i.e., in-clinic cytology or colposcopy).[20] If patients do not have an established local provider for this referral, we connect them to one.

Guideline-based Referrals and Follow-up Testing

Follow-up care is as important as screening. Teal medical providers refer patients for an in-clinic Pap test or colposcopy, based on **ASCCP Self-Collect Clinical Management Guidelines.**[20]



Our multi-step approach to ensuring follow-up care engagement

Supporting patients

1. Teal providers refer patients to their established Primary Care or OBGYN.
2. When patients do not have established providers, we identify a suitable local provider through our robust referral network system.
3. The Teal team offers referral scheduling assistance when patients need support.
4. Multi-channel communication consistently reminds and encourages patients to schedule their referral.

Supporting referred providers

1. Teal shares the necessary documentation and results to support the referral process.
2. Teal remains engaged with referred providers to obtain follow-up results and updates patient medical records to track future screening needs.

Studies show that women are more likely to engage in follow-up care after self-collection, especially with high-touch reminders and support.

- Across 24 trials, follow-up rates after self-collection ranged from 88.6% to 99.8%.[4]
- Among underscreened groups, follow-up rates often exceed 70% - up to 85% to 95% when telehealth and patient navigation are available.[19,21]

Teal Health is a member of the National Roundtable on Cervical Cancer.

A widely available at-home option for cervical cancer screening that both you and your patient can trust.

At-home self-collection can expand care. Meeting patients where they are gives us a better chance of catching cervical cancer earlier in people who might go unscreened.

Teal's FDA-authorized Teal Wand self-collection device and our dedicated team are here to work with you, as an extension of the important care you provide.

We have seen other countries make strides toward ending cervical cancer in the past years, and we hope we can work together to do the same for women here.

Pictured: Select members of the Teal Medical Provider team

For any questions or to share your thoughts, please contact help@tealhealth.co.

If you have a patient who is interested in screening at home, please direct them to getteal.com.

Teal Health is available in all 50 U.S. states.

We look forward to helping you continue caring for your patients and keeping them healthy.

Teal Health is a member of the Cervical Cancer Roundtable, a joint collaboration between the American Cancer Society and the Cancer Moonshot, a coalition of industry leaders with the goal of eliminating cervical cancer as a public health concern in the US.

Teal Health is a member of the National Roundtable on Cervical Cancer.

References

1. Fitzpatrick MB, Behrens CM, Hibler K, Parsons C, Kaplan C, Orso R, et al. Clinical Validation of a Vaginal Cervical Cancer Screening Self-Collection Method for At-Home Use: A Nonrandomized Clinical Trial. JAMA Netw Open 2025;8:e2511081. https://doi.org/10.1001/jamanetworkopen.2025.11081.
2. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136(2):189-197. doi:10.1016/j.ygyno.2014.11.076
3. Castle PE, Stoler MH, Wright TC, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12(9):880-890. doi:10.1016/S1470-2045(11)70188-7
4. United States Preventive Services Taskforce. Draft Evidence Review: Cervical Cancer: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/document/draft-evidence-review/cervical-cancer-screening-adults-adolescents. Accessed February 8, 2025.
5. Marcus JZ, Cason P, Downs LS Jr, Einstein MH, Flowers L. The ASCCP Cervical Cancer Screening Task Force endorsement and opinion on the American Cancer Society updated cervical cancer screening guidelines. J Low Genit Tract Dis. 2021;25(2):187-191. doi:10.1097/LGT.0000000000000614
6. Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321-346. doi:10.3322/caac.21628
7. Sawaya GF, Huchko MJ. Cervical cancer screening: Past, present, and future. Cancer Epidemiol Biomarkers Prev. 2021;30(3):432-434. doi:10.1158/1055-9965.EPI-20-1670
8. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10-45. doi:10.3322/caac.21871
9. Office of Disease Prevention and Health Promotion. Increase the proportion of females who get screened for cervical cancer — C-09 - Healthy People 2030. https://health.gov/healthypeople/objectives-and-data/browse-objectives/cancer/increase-proportion-females-who-get-screened-cervical-cancer-c-09. Accessed February 1, 2024.
10. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524-532. doi:10.1016/S0140-6736(13)62218-7
11. Subramaniam A, Fauci J, Schneider K, et al. Invasive cervical cancer and screening: What are the rates of unscreened and underscreened women in the modern era? J Low Genit Tract Dis. 2011;15(2):110-113. doi:10.1097/LGT.0b013e3181f515a2
12. Kim M, Kim H, Suh DH, Kim YB. Cervical cancer in women with normal Papanicolaou tests: A Korean nationwide cohort study. Cancer Res Treat. 2021;53(3):813-818. doi:10.4143/crt.2020.826
13. Kim M, Kim H, Suh DH, Kim YB. Cervical cancer in women with normal Papanicolaou tests: A Korean nationwide cohort study. Cancer Res Treat. 2021;53(3):813-818. doi:10.4143/crt.2020.826
14. Fuzzell LN, Perkins RB, Christy SM, Lake PW, Sheinfeld Gorin S. Cervical cancer screening in the United States: challenges and potential solutions for underscreened populations. Prev Med. 2022;155:106927. doi:10.1016/j.ypmed.2021.106927 [From: https://pubmed.ncbi.nlm.nih.gov/34861338/]
15. Bednarczyk RA, Rice WS, Starr K, et al. Improving cervical cancer screening among women with behavioral health conditions: a randomized pragmatic trial. Am J Prev Med. 2023;64(5):592-600. doi:10.1016/j.amepre.2023.01.004 [From: https://pubmed.ncbi.nlm.nih.gov/36980555/]
16. Winer RL, Lin J, Tiro JA, et al. Effect of mailed human papillomavirus test kits vs usual care reminders on cervical cancer screening uptake, precancer detection, and treatment: a randomized clinical trial. JAMA Netw Open. 2019;2(11):e1914729. doi:10.1001/jamanetworkopen.2019.14729
17. Pretsch PK, Spees LP, Brewer NT, et al. Effect of HPV self-collection kits on cervical cancer screening uptake among under-screened women from low-income US backgrounds (MBMT-3): a phase 3, open-label, randomised controlled trial. Lancet Public Health. 2023;8(6):e411-e421. doi:10.1016/S2468-2667(23)00076-2
18. Arbyn M, Smith SB, Temin S, Sultana F, Castle P; Collaboration on Self-Sampling and HPV Testing. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018;363:k4823. doi:10.1136/bmj.k4823
19. United States Preventive Services Taskforce. Draft Evidence Review: Cervical Cancer: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/document/draft-evidence-review/cervical-cancer-screening-adults-adolescents. Accessed February 8, 2025.
20. Gupta S, Palmer C, Bik EM, et al. Self-sampling for human papillomavirus testing: increased cervical cancer screening participation and incorporation in international screening programs. Front Public Health. 2018;6:77. doi:10.3389/fpubh.2018.00077
21. Wentzensen N, Massad LS, Clarke MA, Garcia F, Smith R, Murphy J, et al. Self-collected vaginal specimens for HPV testing: recommendations from the Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee. J Low Genit Tract Dis. 2025;29(2):144-152. doi:10.1097/LGT.0000000000000885
22. Smith LW, Booth A, Racey CS, Smith B, Prabhakaran A, Dabee S, et al. Self-screening for cervical cancer offered through a digital platform in a region of British Columbia with lower screening rates. Curr Oncol. 2024;31(9):5399-5411. doi:10.3390/curroncol31090399
23. Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041
24. U.S. Department of Health and Human Services Health Resources and Services Administration. New Cervical Cancer Screening Guidelines Strengthen Women's Preventive Health. https://www.hrsa.gov/about/news/press-releases/new-cervical-cancer-screening-guidelines. Accessed January 5, 2026